MNKD

Business Context and Reporting Period

MannKind Corporation (MNKD) is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases. The company commercializes Afrezza (inhaled insulin), Furoscix (subcutaneous furosemide), and V-Go (wearable insulin delivery). It also manufactures Tyvaso DPI for partner United Therapeutics (UT). This Form 10-Q covers the quarterly period ended March 31, 2026.

Key strategic developments in the period include the integration of the October 2025 acquisition of scPharmaceuticals (scPharma), which added Furoscix to the portfolio, and the settlement of remaining senior convertible notes in March 2026.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 15% year-over-year, driven by a 79% increase in commercial product sales. This was primarily due to the inclusion of Furoscix revenue ($15.5 million) following the scPharma acquisition. Royalty revenue from UT increased 9% to $32.7 million.
• Expense Surge: Total expenses rose 64% to $91.8 million. Selling, general, and administrative (SG&A) expenses more than doubled (116% increase) due to Furoscix promotion and expanded Afrezza field teams. R&D expenses increased 56% due to scPharma integration and MNKD-201 development.
• Profitability Shift: The company swung from a net income of $13.2 million in Q1 2025 to a net loss of $16.6 million in Q1 2026. This was driven by higher operating expenses, amortization of acquired intangible assets ($4.4 million), and significant non-operating expenses.
• Debt Settlement: The company settled the remaining $36.3 million principal of its senior convertible notes in March 2026, resulting in a $0.9 million loss on settlement of debt.
• Contingent Consideration: A $2.8 million expense was recorded due to the remeasurement of the fair value of contingent consideration liabilities from the scPharma acquisition.

Guidance, Outlook, and Risks

• Regulatory Milestones: The FDA is reviewing a supplemental biologics license application (sBLA) for pediatric Afrezza (PDUFA date: May 29, 2026) and a supplemental new drug application (sNDA) for Furoscix ReadyFlow Autoinjector (PDUFA date: July 26, 2026).
• Liquidity: Management believes current cash, cash equivalents, and investments ($133.9 million total) combined with operating cash flows and the Blackstone Credit Facility are sufficient to fund operations for at least the next 12 months.
• Debt Covenants: The company is subject to a liquidity covenant requiring at least $40.0 million in unrestricted cash and cash equivalents. As of March 31, 2026, the company was in compliance.
• Key Risks:
  • United Therapeutics Strategy: Revenue is heavily dependent on UT's commercialization of Tyvaso DPI. UT has indicated a potential shift in focus to a new product (Tresmi), which could materially reduce Tyvaso DPI sales and MannKind's royalties.
  • Supply Chain & Tariffs: V-Go is manufactured in China; Furoscix components are sourced globally. Tariffs or trade restrictions could increase costs.
  • Insulin Commitments: The company has significant long-term purchase commitments for insulin (€55.2 million remaining) with Amphastar, creating exposure to foreign exchange rates and potential inventory obsolescence.

Investor Verification Checklist

• Verify the status of the FDA reviews for pediatric Afrezza and Furoscix ReadyFlow Autoinjector against the stated PDUFA dates.
• Monitor United Therapeutics' sales data for Tyvaso DPI and any public statements regarding resource allocation between Tyvaso DPI and Tresmi.
• Review the company's ability to maintain the $40 million liquidity covenant under the Blackstone Credit Facility given the recent cash burn.
• Assess the impact of the scPharma acquisition integration on future R&D and SG&A expense trajectories.
• Confirm the valuation assumptions used for the contingent consideration liability related to the scPharma CVRs, which fluctuated significantly in Q1 2026.